Table 2.

Prevalence at enrollment and 12-month cumulative incidence of oral human papillomavirus (HPV) infection in young men, overall and by type,^* University of Washington Oral Human Papillomavirus (HPV) Cohort

HPV type(s)#	Prevalence, no. (%)	Incidence at 12 mo., no. of infections/person-yr	Cumulative incidence at 12 mo., % (95% CI)	Total no. of incident infections
Any type$	16 (7.5)	12/134	12.3 (7.0, 21.3)	17
By swab	8 (3.8)	11/144	9.3 (5.0, 16.7)	15
By gargle/rinse	11 (5.2)	7/136	6.3 (2.9, 13.3)	8
Multiple types&	9 (4.2)	4/145	3.3 (1.2, 8.9)	6
6£	1 (0.5)	0/146	0	0
16	6 (2.8)	1/142	0.8 (0.1, 5.7)	2
18	5 (2.4)	2/144	2.7 (0.7, 10.2)	2
31	3 (1.4)	1/143	1.3 (0.2, 8.8)	1
33	4 (1.9)	0/144	0	1
35	1 (0.5)	1/144	0.6 (0.1, 3.9)	1
39	4 (1.9)	3/142	2.3 (0.7, 7.1)	3
45	1 (0.5)	0/146	0	1
51	2 (0.9)	2/144	2 (0.5, 8.6)	3
52	1 (0.5)	2/146	1.9 (0.4, 7.9)	2
53	0 (0)	1/146	0.9 (0.1, 6.0)	1
55	2 (0.9)	0/145	0	0
59	1 (0.5)	0/145	0	0
62	1 (0.5)	0/146	0	2
66	1 (0.5)	0/145	0	2
81	1 (0.5)	0/145	0	1
83	0 (0)	1/146	0.9 (0.1, 6.0)	1
84	0 (0)	2/146	1.2 (0.3, 4.6)	2

^*There were no prevalent or incident infections of HPV types 11, 26, 40, 42, 54, 56, 58, 64, 68, 69, 70, 72, 73, 82, cp6108, and is39.

^#Detected by swab or gargle/rinse unless otherwise indicated

^$Participants with any oral HPV infection at baseline were excluded from the calculation of incidence for “Any type”

^&Among prevalent and incident infections, respectively

^£Participants were excluded from the calculation of oral HPV incidence by type if they were positive for that HPV type at baseline